Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)†

Article English OPEN
Gerber, B.; Loibl, S.; Eidtmann, H.; Rezai, M.; Fasching, P. A.; Tesch, H.; Eggemann, H.; Schrader, I.; Kittel, K.; Hanusch, C.; Kreienberg, R.; Solbach, C.; Jackisch, C.; Kunz, G.; Blohmer, J. U.; Huober, J.; Hauschild, M.; Nekljudova, V.; Untch, M.; von Minckwitz, G.; (2017)

Background We evaluated the pathological complete response (pCR) rate after neoadjuvant epirubicin, (E) cyclophosphamide (C) and docetaxel containing chemotherapy with and without the addition of bevacizumab in patients with triple-negative breast cancer (TNBC). Patient... View more
Share - Bookmark